You are here
Friday, April 17, 2020
Investigational chimp adenovirus MERS-CoV vaccine protects monkeys
Vaccine neutralizes multiple MERS-CoV strains.
An investigational vaccine called ChAdOx1 MERS protected two groups of rhesus macaques from disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV is a relative of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). National Institutes of Health scientists and colleagues are pursuing similar studies with ChAdOx1 SARS2, a vaccine candidate against SARS-CoV-2. They posted their results with ChAdOx1 MERS on a preprint server. The findings are not yet peer-reviewed but are being shared to assist the public health response to COVID-19.
ChAdOx1 MERS, which uses a replication-deficient chimpanzee adenovirus to deliver a MERS-CoV protein in recipients, also worked against six different strains of MERS-CoV when tested in mice as a single vaccination. Scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) at Rocky Mountain Laboratories in Hamilton, Mont., led the project. Collaborators work at the University of Oxford in the United Kingdom; researchers at the University of Oxford Jenner Institute developed the ChAdOx1 vaccine technology.
Human cases of MERS-CoV were first reported in Saudi Arabia in 2012; dromedary camels are also infected with the virus and likely transmit it to people. MERS-CoV causes disease deep in the lungs, leading to pneumonia among infected individuals. Through January 2020, the World Health Organization had received reports of 2,519 MERS-CoV cases and 866 deaths in 27 countries.
In the macaque study, one group of animals was vaccinated 28 days prior to infection; the other group received two vaccinations—a prime-boost strategy—56 and 28 days prior to infection. A third group of monkeys served as controls. The scientists report that none of the animals in the two treatment groups developed signs of MERS-CoV disease. The prime-boost group clearly had less virus in lung tissue compared to the control group and no evidence of replicating virus, while the prime-only group showed much less virus in tissue than the control group. Both treatment groups showed no lung damage and were protected from disease, unlike the control animals.
The scientists’ MERS-CoV macaque study follows earlier studies of the experimental vaccine in mice. They also have successfully tested the vaccine platform against Nipah virus in hamsters and against Lassa virus in guinea pigs; they next plan to expedite testing a vaccine candidate against SARS-CoV-2.
The MERS vaccine is being studied in Phase 1 human clinical trials in the United Kingdom and Saudi Arabia. The same chimpanzee adenovirus vaccine platform also is being assessed for malaria, HIV, influenza, hepatitis C, tuberculosis and Ebola.
N van Doremalen et al. A single dose of ChAdOx1 MERS provides broad protective immunity against a variety of MERS-CoV strains.
Vincent Munster, Ph.D., and Marshall Bloom, M.D., of NIAID’s Laboratory of Virology, are available to comment on this study.
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®